Arctic Bioscience AS
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as int… Read more
Arctic Bioscience AS (ABS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.054x
Based on the latest financial reports, Arctic Bioscience AS (ABS) has a cash flow conversion efficiency ratio of -0.054x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-12.80 Million) by net assets (Nkr235.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Arctic Bioscience AS - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Arctic Bioscience AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Arctic Bioscience AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arctic Bioscience AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alice QUEEN Ltd
AU:AQX
|
-126.430x |
|
Copper Road Resources Inc.
V:CRD
|
-0.022x |
|
Exploits Discovery Corp
OTCQX:NFLDF
|
-0.041x |
|
Damai Sejahtera Abadi Tbk PT
JK:UFOE
|
-0.017x |
|
Panamax AG
F:ICP
|
N/A |
|
Salee Printing Public Company Limited
BK:SLP
|
0.023x |
|
BAB Inc
OTCQB:BABB
|
0.055x |
|
Genetic Technologies Ltd
NASDAQ:GENE
|
-3.096x |
Annual Cash Flow Conversion Efficiency for Arctic Bioscience AS (2019–2024)
The table below shows the annual cash flow conversion efficiency of Arctic Bioscience AS from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr210.73 Million | Nkr-45.36 Million | -0.215x | -38.14% |
| 2023-12-31 | Nkr258.56 Million | Nkr-40.29 Million | -0.156x | -76.26% |
| 2022-12-31 | Nkr287.28 Million | Nkr-25.40 Million | -0.088x | +28.25% |
| 2021-12-31 | Nkr320.55 Million | Nkr-39.49 Million | -0.123x | +64.01% |
| 2020-12-31 | Nkr63.94 Million | Nkr-21.89 Million | -0.342x | -1112.85% |
| 2019-12-31 | Nkr63.90 Million | Nkr2.16 Million | 0.034x | -- |